Physician profile
Robert Murphy Portley
NPI 1417299819
$1,685.36
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $119 · 2021: $318 · 2022: $475.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $535.78 | 2019-2020 | |
| Alkermes, INC. | $281.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.51 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.66 | 2020-2022 | |
| Tris Pharma INC | $105.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $103.11 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.33 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $58.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.47 | 2019 | |
| Indivior INC. | $36.08 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.32 | 2019 | |
| Abbvie INC. | $19.80 | 2021 | |
| Shire North American Group INC | $14.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Portley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.